1. Home
  2. OP vs CYCN Comparison

OP vs CYCN Comparison

Compare OP & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OP
  • CYCN
  • Stock Information
  • Founded
  • OP 2021
  • CYCN 2018
  • Country
  • OP Greece
  • CYCN United States
  • Employees
  • OP N/A
  • CYCN N/A
  • Industry
  • OP
  • CYCN Biotechnology: Pharmaceutical Preparations
  • Sector
  • OP
  • CYCN Health Care
  • Exchange
  • OP Nasdaq
  • CYCN Nasdaq
  • Market Cap
  • OP 8.5M
  • CYCN 8.4M
  • IPO Year
  • OP N/A
  • CYCN N/A
  • Fundamental
  • Price
  • OP $1.13
  • CYCN $3.26
  • Analyst Decision
  • OP
  • CYCN
  • Analyst Count
  • OP 0
  • CYCN 0
  • Target Price
  • OP N/A
  • CYCN N/A
  • AVG Volume (30 Days)
  • OP 11.1K
  • CYCN 5.8M
  • Earning Date
  • OP 12-20-2024
  • CYCN 03-04-2025
  • Dividend Yield
  • OP N/A
  • CYCN N/A
  • EPS Growth
  • OP N/A
  • CYCN N/A
  • EPS
  • OP N/A
  • CYCN N/A
  • Revenue
  • OP $25,729,000.00
  • CYCN $194,000.00
  • Revenue This Year
  • OP N/A
  • CYCN N/A
  • Revenue Next Year
  • OP N/A
  • CYCN N/A
  • P/E Ratio
  • OP N/A
  • CYCN N/A
  • Revenue Growth
  • OP 36.33
  • CYCN N/A
  • 52 Week Low
  • OP $1.02
  • CYCN $1.27
  • 52 Week High
  • OP $3.15
  • CYCN $9.47
  • Technical
  • Relative Strength Index (RSI)
  • OP 40.22
  • CYCN 56.08
  • Support Level
  • OP $1.11
  • CYCN $2.81
  • Resistance Level
  • OP $1.24
  • CYCN $4.80
  • Average True Range (ATR)
  • OP 0.05
  • CYCN 0.68
  • MACD
  • OP -0.00
  • CYCN 0.13
  • Stochastic Oscillator
  • OP 7.17
  • CYCN 43.54

About OP OceanPal Inc.

OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary.

About CYCN Cyclerion Therapeutics Inc.

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Share on Social Networks: